
|Podcasts|May 26, 2022
New Guidance For Biopharma Investor ESG Communications
Author(s)Elaine Quilici, Miranda Schmalfuhs
Advertisement
Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
2
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
3
Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics
4
The New Healthy Aging Imperative and What It Means for Pharma
5
